Destiny Pharma PLC DEST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 23.00
- Day Range
- GBX 21.63–23.50
- 52-Week Range
- GBX 15.55–84.00
- Bid/Ask
- GBX 21.00 / GBX 22.50
- Market Cap
- GBX 2.10 Bil
- Volume/Avg
- 262,684 / 446,606
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.destinypharma.com
Valuation
|
Metric
|
DEST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.54 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DEST
|
|---|---|
Quick Ratio | 9.48 |
Current Ratio | 9.48 |
Interest Coverage | — |
Quick Ratio
DEST
Profitability
|
Metric
|
DEST
|
|---|---|
Return on Assets (Normalized) | −50.20% |
Return on Equity (Normalized) | −55.38% |
Return on Invested Capital (Normalized) | −56.72% |
Return on Assets
DEST
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ldsdtcltb | Kwpl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qzmlmjpg | Mytyf | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zdqvzwj | Khnmgl | $98.8 Bil | |
MRNA
| Moderna Inc | Rmndpvlc | Gzq | $38.8 Bil | |
ARGX
| argenx SE ADR | Qwjcshxp | Vbqkr | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Fyxcjnh | Wkpg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Csqpdzls | Gpcdndr | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tpszfbrv | Vnxhgt | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jtlpvvzv | Xqxvd | $12.4 Bil | |
INCY
| Incyte Corp | Vxsqqqtd | Flgchht | $11.9 Bil |